In two studies, scientists at Gilead, which developed lenacapavir, showed that the drug was 100% effective at protecting cisgender women from becoming HIV positive as compared to daily oral pills ...

WASHINGTON D.C., DC — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it's ...

WASHINGTON D.C., DC — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it's ...

WASHINGTON D.C., DC — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it's unclear how ...

WASHINGTON D.C., DC — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it's ...

WASHINGTON D.C., DC — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it's ...

WASHINGTON D.C., DC — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it's ...

WASHINGTON D.C., DC — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it's ...

WASHINGTON D.C., DC — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it's ...